PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
Recruiting · NCT05009797 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Lille
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
Who can take part
Inclusion criteria
- Patient undergoing atrial fibrillation catheter ablation
- Able to give their consent
Exclusion criteria
- Childs
- Patient under guardianship
- Patients unable to give their consent
- Pregnancy
Where it is running
1 location listed.
- Institut Coeur-Poumon, CHU - Lille, France